ARCHIVES

ODAC Nixes Abraxane for Adjuvant Breast Cancer, While Genasense Falls Victim to Its Randomized Trial.

This article is from The Cancer Letter archive.

Vol. 32 No. 31 | September 8, 2006

Download PDF Visit The Full Archive

Related Articles

Southwest Oncology Group Becomes “SWOG”

April 8, 2011

In Brief: Grants Compromise Still In Doubt As Natcher, Conte Hold Out for 6,500; House Marks Up Bill

July 12, 1985

Cervarix Vaccine Approved To Prevent Cervical Cancer

October 30, 2009

Elderly and Younger Patients Have Similar Outcomes Following Radioembolization

July 26, 2013

Proceedings Initiated Against Two Physicians At Dana-Farber

April 7, 1995

Clinical Trial Pathology Improvements Recommended By Group Remaining Actions After Merit Review

January 12, 1979